TG Therapeutics Inc
$ 49.76
0.42%
07 Aug - close price
- Market Cap 7,617,439,000 USD
- Current Price $ 49.76
- High / Low $ 50.19 / 49.11
- Stock P/E 18.16
- Book Value 4.11
- EPS 2.74
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 1.13 %
- 52 Week High 59.30
- 52 Week Low 25.28
About
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Analyst Target Price
$76.67
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-03 | 2026-05-06 | 2026-02-26 | 2025-11-03 | 2025-08-04 | 2025-05-05 | 2025-03-03 | 2024-11-04 | 2024-08-06 | 2024-05-01 | 2024-02-28 | 2023-11-01 |
| Reported EPS | 0.05 | 0.18 | 0.14 | 0.16 | 0.17 | 0.03 | 0.15 | 0.02 | 0.04 | -0.07 | -0.1 | 0.73 |
| Estimated EPS | 0.41 | 0.28 | 0.35 | 0.22 | 0.29 | 0.17 | 0.09 | 0.03 | -0.04 | -0.04 | -0.1 | 0.1 |
| Surprise | -0.36 | -0.1 | -0.21 | -0.06 | -0.12 | -0.14 | 0.06 | -0.01 | 0.08 | -0.03 | 0 | 0.63 |
| Surprise Percentage | -87.8049% | -35.7143% | -60% | -27.2727% | -41.3793% | -82.3529% | 66.6667% | -33.3333% | 200% | -75% | 0% | 630% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TGTX
2026-08-05 21:42:06
This article lists various ETFs that invest in TG Therapeutics, Inc. stocks, providing detailed information such as market value, weight, issuer, management style, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV total return for each fund. The ETFs primarily focus on small-cap, total market, or health care sectors, offering investors diverse options to gain exposure to TG Therapeutics, Inc. through lower-risk investment vehicles.
2026-08-05 21:31:51
TG Therapeutics reported its 2026 quarterly results with revenue of $240.34 million, an increase from $141.15 million in the prior year, and diluted EPS of $0.05, down from $0.17. The net income for the quarter was $7.78 million, compared to $28.19 million in the year-ago period. Revenue growth was primarily driven by increased U.S. penetration and ex-U.S. sales through a partner, along with continued adoption of BRIUMVI following FDA approval and positive clinical trial results for its pipeline.
2026-08-05 21:31:51
TG Therapeutics (NASDAQ: TGTX) reported strong financial results for the first half of 2026, with total revenue reaching $445.3 million, primarily driven by BRIUMVI sales for multiple sclerosis both in the U.S. and internationally. The company achieved profitability, posting a net income of $27.6 million for the period, and anticipates existing liquidity and projected revenues will fund operations for over twelve months without needing to raise additional capital. TG Therapeutics also highlighted progress in its clinical pipeline, including positive Phase 3 topline data for a simplified BRIUMVI dosing regimen and Phase 1 data for subcutaneous ublituximab, alongside initiating new trials for BRIUMVI in myasthenia gravis and schizophrenia.
2026-08-04 12:41:24
H.C. Wainwright has increased its price target for TG Therapeutics (NASDAQ:TGTX) to $78 from $77, maintaining a Buy rating after the company's strong second-quarter 2026 earnings report. The firm noted Briumvi's US revenue exceeded estimates and its market share grew, leading TG Therapeutics to raise its 2026 total global revenue guidance. Despite a slight dip in share price post-earnings, the stock has shown significant year-over-year returns, and an InvestingPro analysis suggests it is undervalued.
2026-08-04 10:41:24
TG Therapeutics (TGTX) stock is currently viewed as undervalued, despite a significant 3-year return. The company's P/E ratio is lower than both the biotech industry average and its peers, suggesting a discount relative to its fundamentals. While strong revenue growth from BRIUMVI is positive, earnings have fallen short of some expectations, prompting questions about the market's caution regarding its long-term profitability.
2026-08-04 06:41:24
TG Therapeutics announced strong second-quarter 2026 financial results, with total global revenue reaching approximately $240 million and U.S. BRIUMVI® net product revenue at $228 million. The company has raised its full-year 2026 revenue guidance for both total global revenue to $950 million and U.S. BRIUMVI® net product revenue to between $890 million and $905 million. This positive outlook is driven by excellent commercial performance and progress in BRIUMVI®'s subcutaneous program, a simplified initiation regimen, and expansion into myasthenia gravis and schizophrenia indications.
